Logan Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,568
| Closed | -$449K | – | 396 |
|
|
2025
Q4 | $437K | Hold |
2,568
| – | – | 0.02% | 246 |
|
|
2025
Q3 | $338K | Buy |
2,568
+1,474
| +135% | +$177K | 0.01% | 251 |
|
|
2025
Q2 | $116K | Sell |
1,094
-1,594
| -59% | -$173K | 0.01% | 280 |
|
|
2025
Q1 | $334K | Sell |
2,688
-68
| -2% | -$8.87K | 0.02% | 261 |
|
|
2024
Q4 | $339K | Sell |
2,756
-1,183
| -30% | -$139K | 0.01% | 265 |
|
|
2024
Q3 | $439K | Sell |
3,939
-16
| -0.4% | -$1.75K | 0.02% | 252 |
|
|
2024
Q2 | $422K | Buy |
3,955
+31
| +0.8% | +$3.41K | 0.02% | 251 |
|
|
2024
Q1 | $473K | Buy |
3,924
+20
| +0.5% | +$2.45K | 0.02% | 246 |
|
|
2023
Q4 | $480K | Buy |
3,904
+180
| +5% | +$22.5K | 0.02% | 248 |
|
|
2023
Q3 | $482K | Buy |
3,724
+33
| +0.9% | +$4.4K | 0.02% | 242 |
|
|
2023
Q2 | $458K | Hold |
3,691
| – | – | 0.02% | 246 |
|
|
2023
Q1 | $540K | Sell |
3,691
-225
| -6% | -$33.3K | 0.03% | 249 |
|
|
2022
Q4 | $624K | Sell |
3,916
-141
| -3% | -$20.7K | 0.03% | 238 |
|
|
2022
Q3 | $541K | Hold |
4,057
| – | – | 0.03% | 233 |
|
|
2022
Q2 | $633K | Sell |
4,057
-255
| -6% | -$39.3K | 0.04% | 233 |
|
|
2022
Q1 | $671K | Buy |
4,312
+2,824
| +190% | +$410K | 0.03% | 241 |
|
|
2021
Q4 | $190K | Sell |
1,488
-2,664
| -64% | -$350K | 0.01% | 295 |
|
|
2021
Q3 | $541K | Buy |
4,152
+678
| +20% | +$102K | 0.03% | 252 |
|
|
2021
Q2 | $617K | Buy |
3,474
+2,577
| +287% | +$446K | 0.03% | 245 |
|
|
2021
Q1 | $147K | Buy |
+897
| New | +$148K | 0.01% | 294 |
|
|
2017
Q4 | – | Sell |
-1,599
| Closed | -$234K | – | 280 |
|
|
2017
Q3 | $234K | Buy |
1,599
+60
| +4% | +$9.07K | 0.02% | 269 |
|
|
2017
Q2 | $239K | Hold |
1,539
| – | – | 0.02% | 260 |
|
|
2017
Q1 | $223K | Buy |
+1,539
| New | +$200K | 0.02% | 260 |
|
|
2016
Q3 | – | Sell |
-1,539
| Closed | -$217K | – | 266 |
|
|
2016
Q2 | $217K | Hold |
1,539
| – | – | 0.02% | 254 |
|
|
2016
Q1 | $201K | Hold |
1,539
| – | – | 0.02% | 280 |
|
|
2015
Q4 | $216K | Hold |
1,539
| – | – | 0.02% | 274 |
|
|
2015
Q3 | $204K | Hold |
1,539
| – | – | 0.02% | 275 |
|
|
2015
Q2 | $271K | Buy |
+1,539
| New | +$276K | 0.02% | 277 |
|
Other funds holding JAZZ
VPM
VCM
EC
Logan Capital Management's JAZZ Position: Q1 2026 in Review
Logan Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 2,568 shares — an estimated $449K sold.
Logan Capital Management first reported a position in JAZZ in Q2 2015 and held it in 28 quarters. The position peaked at $671K in Q1 2022. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Logan Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Logan Capital Management sold 2,568 Jazz Pharmaceuticals shares in Q1 2026, an estimated $449K.
- Logan Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2015 and held it in 28 quarters.
- Logan Capital Management's Jazz Pharmaceuticals position peaked at $671K in Q1 2022.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Logan Capital Management's 13F filing for Q1 2026, filed 8 May 2026.